Print Page  |  Close Window

Investors


Corporate Profile

Rigel’s current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The company has submitted an NDA to the FDA for fostamatinib in patients with chronic or persistent ITP. The investigation of fostamatinib also includes Phase 2 clinical trials for autoimmune hemolytic anemia (AIHA) and IgA nephropathy (IgAN). In addition, Rigel has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics.

Recent News

More »
DateTitle 
10/10/17Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Oct. 10, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NasdaqGS: RIGL) today announced the closing of its previously announced underwritten public offering of 20,815,000 shares of its common stock at a price to the public of $3.35 per share, which includes 2,715,000 additional shares of common stock issued upon the exercise in full of the underwriters' option to purchase additional shares.  The gross proceeds to Rigel from this offering are $69,730,250, before de... 
Printer Friendly Version
10/04/17Rigel Announces Pricing Of Public Offering Of Common Stock
SOUTH SAN FRANCISCO, Calif., Oct. 4, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NasdaqGS: RIGL), today announced the pricing of its previously announced underwritten public offering of 18,100,000 shares of its common stock, offered at a price of $3.35 per share to the public.  The gross proceeds to Rigel from this offering are expected to be $60,635,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Rigel.  All of the shares in th... 
Printer Friendly Version
10/03/17Rigel Announces Proposed Public Offering Of Common Stock
SOUTH SAN FRANCISCO, Calif., Oct. 3, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it intends to offer and sell up to $40,000,000 of shares of its common stock in an underwritten public offering. Rigel expects to grant the underwriters a 30-day option to purchase up to an additional $6,000,000 of shares of common stock sold in the public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no as... 
Printer Friendly Version

Upcoming Events

More »

There are currently no events scheduled.

Stock Quote

RIGL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$4.23
Change (%) + 0.36 (9.30%)
Volume3,597,812
Data as of 10/17/17 4:00 p.m. ET   Refresh quote

Stock Chart

Stock chart for: RIGL.O.  Currently trading at $4.23 with a 52 week high of $4.07 and a 52 week low of $1.94.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources

E-mail Alerts

Sign up to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site. Just enter your e-mail address and click Submit.